MiniMed Group (MMED) news centers on diabetes technology, insulin delivery systems, CGM integrations, automated insulin delivery algorithms, and the company's development as a newly public Nasdaq-listed medical device business. MiniMed describes itself as a global leader in insulin delivery, with therapies supporting people with diabetes in more than 80 countries.
MMED headlines often matter because the company operates in a regulated care category where product access, sensor compatibility, clinical evidence, reimbursement availability, and regulatory clearances can affect adoption. Company announcements have covered U.S. and European product launches, MiniMed Flex™ availability, Instinct sensors made by Abbott, SmartGuard™ technology, Medicare and Medicare Advantage access, FDA-related activity, CE Mark activity, and pivotal trial updates.
Investors following MiniMed news also watch earnings releases, investor conference participation, board updates, separation-related developments, Medtronic ownership context, and SEC-filed material event reports. Because MiniMed's ecosystem combines pumps, sensors, algorithms, apps, and service, product news can touch several parts of the diabetes management experience at once.
Frequent review of MMED news can help track how MiniMed communicates product availability, regulatory progress, clinical evidence, financial results, and governance changes as an independent public company in diabetes technology.
MiniMed (Nasdaq: MMED) announced its board composition following completion of its separation from Medtronic, with Kevin E. Lofton remaining chair. Amy Bricker joins effective immediately as part of the planned transition from Medtronic-designated directors to the company's post-separation board.
The board also includes MiniMed CEO Que Dallara, Glenn Eisenberg, David Endicott, Keith Grossman, Bob Hopkins and Timothy Wicks. Eisenberg chairs the Audit Committee, Grossman chairs the Nominating & Corporate Governance Committee, and Wicks chairs the Compensation & Talent Committee. Bricker, executive vice president of Enterprise Pharmacy at Walgreens and former president of Express Scripts, joins the Nominating & Corporate Governance Committee. MiniMed said the board's composition supports its priorities of growth, innovation, execution and broader access to diabetes technology as an independent public company.
Summary not available.
Medtronic (NYSE: MDT) has completed its separation of MiniMed Group, ending its remaining ownership through a share exchange offer. Medtronic elected to exchange all 252,813,348 MiniMed common shares it still held for outstanding Medtronic ordinary shares. The exchange offer was 5.4x subscribed. MiniMed trades under Nasdaq: MMED, and accepted tendering shareholders will receive MiniMed shares in book-entry form.
MiniMed (MMED) completed its separation from Medtronic (MDT), marking its first day as a fully independent company.
Medtronic accepted 55,032,401 ordinary shares in exchange for 252,813,348 MiniMed common shares and no longer holds an equity stake in MiniMed. The exchange offer was 5.4x subscribed.
Medtronic (MDT) announced final results of its oversubscribed exchange offer and elected to exchange its entire remaining MiniMed (MMED) stake.
Medtronic will exchange 252,813,348 MiniMed shares for 55,032,401 Medtronic ordinary shares. The final proration factor is 18.289133%, except for eligible odd-lot tenders. The offer expired October 9, 2026. After completion, Medtronic will hold no MiniMed common shares.
Medtronic (MDT) announced preliminary results showing its MiniMed exchange offer was oversubscribed after expiring on October 9, 2026. Medtronic intends to accept 55,032,401 ordinary shares in exchange for its remaining 252,813,348 MiniMed shares, at 4.5939 MiniMed shares per accepted Medtronic share. Approximately 18.3% of tendered shares are estimated to be exchanged, subject to guaranteed deliveries. Medtronic expects the final proration factor on October 14, 2026.
Medtronic (NYSE: MDT) set the final exchange ratio for its MiniMed split-off at 4.5939 MiniMed shares per accepted Medtronic share. The offer covers up to 225,361,295 MiniMed shares. If oversubscribed, Medtronic currently intends to exchange its remaining interest as well, adding 27,452,053 shares without extending the offer period. The offer and withdrawal rights expire at midnight, New York City time, at the end of October 9, 2026, unless extended or terminated.
MiniMed (Nasdaq: MMED) presented clinical results linking more frequent responses to Smart MDI alerts with better glucose outcomes in type 1 diabetes.
The six-month randomized trial included 143 people with HbA1c, a measure of average blood glucose, above 8%. Among Smart MDI users, higher responders had, on average, 8.1 percentage points more Time in Range, time within the target glucose range, and 0.6 percentage points lower HbA1c than lower responders. Responding to at least 28% of alerts was associated with improved HbA1c versus multiple daily injections plus continuous glucose monitoring alone.
The system met its primary endpoint, showing glucose outcomes no worse than the comparator. No severe hypoglycemia or diabetic ketoacidosis events were reported in the Smart MDI arm. A real-world analysis of more than 5,500 users found a 9.4 percentage-point Time in Range difference between higher and lower responders; HbA1c was not analyzed.
MiniMed (MMED) appointed Sheila Denton general counsel and corporate secretary, effective immediately, succeeding Courtney Nelson Wills.
Denton most recently held both roles and served on the executive team at Incyte (INCY). Wills left MiniMed to pursue new professional opportunities.
Medtronic (MDT) launched an exchange offer on September 14, 2026 to divest at least 80.1% of MiniMed Group.
MiniMed, its former Diabetes business now trading as MMED, was IPO’d in March 2026, with Medtronic retaining about 90% (252,813,348 shares). The offer lets Medtronic shareholders swap Medtronic ordinary shares for MiniMed common stock, generally on a tax-free basis for U.S. federal income tax purposes, at a 7% discount, subject to an upper limit of 4.5939 MiniMed shares per Medtronic share.
If the cap does not apply, tendering holders are expected to receive MiniMed shares worth about $107.53 for each $100 of Medtronic stock tendered. Medtronic is offering up to 225,361,295 MiniMed shares, and may exchange an additional 27,452,053 shares if the offer is oversubscribed, fully exiting MiniMed. Completion requires at least 112,680,647 MiniMed shares to be issued in the offer and a favorable tax opinion.